RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Meixatech, With the original CX-717 'artifact', they were able to repeat the phenomenon again in subsequent high dose animal tests (and in several species), and also saw it with some other Ampakine compounds but not with others. This wouldn't be the case if the phenomenon was just a one time screw up by the person doing the tissue prep. And the repeatability of the phenomenon means it was not merely an anomaly in a single test animal. So if the observed cellular changes were not due to actual tissue toxicity from the Ampakine (if), they would have to be due to some interaction between certain Ampakines and some aspect or component used in the tissue handling or fixation process.

I don't think Cortex ever revealed the type of tissue where the cellular phenomenon was seen, which adds another layer of uncertainty. And now there is a cellular problem seen in the animal tests of CX-1739, necrosis of cardiac tissue. Even if Cortex's experts conclude that the CX-1739 tissue phenomenon is not a problem, the uncertainty, combined with the previous CX-717 experience, will likely scare away prospective pharma partners from the entire platform. As we know, Ampakines also got a bad rap from the earlier experiences of Lilly and others, and while theirs were high impact compounds, the low impact platform of Cortex is now also tainted, not once but twice.

But such is life in the world of biotech. The amazing respiratory activity of Ampakines will keep Cortex worth following, but luckily there are many other interesting bio stocks to follow.